Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Clinical trial NCT05605899 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05605899
- Sponsor
- Kite, A Gilead Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-10
- Primary completion
- 2031-03-01
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.